Automated Analysis of High-Throughput AC-SINS Assay For Antibody Developability Assessment

Genedata Biopharma Partner Symposium, Basel, Switzerland
March 7, 2024

A main concern during the development of therapeutic antibodies is the assessment of the antibody propensity to aggregate. Such self-interaction liabilities can be detected and triaged during early-stage screening, thanks to the Affinity Capture Self-Interaction Nanoparticle Spectroscopy (AC-SINS) assay. To fully exploit the highthroughput amenability of this assay, Ferring Pharmaceuticals automated end-to-end AC-SINS data quality control and analysis by using the Genedata Screener software.